XERS Shares Outstanding History
Below is a table of the XERS shares outstanding history going back to 6/21/2018:

Date XERS Shares Outstanding

Also see: XERS Market Cap History
XERS Historical Shares Outstanding:
+56.91% CAGR
XERS Historical Shares Outstanding: +56.91% CAGR

Mouse over chart for data details
6/21/2018 ...10/31/2022
Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. We show 20 historical shares outstanding datapoints in our coverage of XERS's shares outstanding history.

Understanding the changing numbers of XERS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like XERS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching XERS by allowing them to research XERS shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree XERS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Xeris Pharmaceuticals (XERS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

XFOR Shares Outstanding History
XGN Shares Outstanding History
XLO Shares Outstanding History
XLRN Shares Outstanding History
XNCR Shares Outstanding History
XOMA Shares Outstanding History
XON Shares Outstanding History
XRAY Shares Outstanding History
YMAB Shares Outstanding History
YMTX Shares Outstanding History
More Healthcare companies »


XERS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2023, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.